Research Article


DOI :10.26650/IUITFD.2019.0053   IUP :10.26650/IUITFD.2019.0053    Full Text (PDF)

THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE

Selçuk Şen

Objective: Clinical trials are essential tools for improving scientific knowledge and public health. With this work, it is aimed to evaluate the clinical trials landscape in Turkey. Method: To evaluate the landscape of clinical trials in Turkey, all clinical trials registered on or before the date of 20.06.2019 in the ClinicalTrials.gov database were used. The registered clinical trials were filtered by study type, study phase, funder type, current status of clinical trials, and location. In addition, the number of clinical trials in Turkey was compared with some countries which were selected based on population and number of trials. Results: In Turkey, the total number of registered clinical trials was 3880. The majority of these trials (%79.4) were interventional studies. The majority of phase trials were phase III studies, of which the vast majority were sponsored by industry. The numbers of completed and currently participants recruiting trials were 2245 and 722, respectively. Not only in Turkey, but in all countries, the numbers of clinical trials with unknown status and phase studies without defined phases were higher in trials were not funded by industry. When the numbers of first registered clinical trials were evaluated between the years of 2009 and 2018, a considerable increase was seen. The number of clinical trials in Turkey was 5 or 6 fold less than in developed countries with a comparable population such as Germany, France, and United Kingdom. Conclusion: With this work, it was shown that the number of clinical trials in Turkey is still not as expected. In order to take its rightful place in the world, Turkey should continue to make improvements, use its potential and increase awareness in the field of clinical trials

DOI :10.26650/IUITFD.2019.0053   IUP :10.26650/IUITFD.2019.0053    Full Text (PDF)

TÜRKİYE’DEKİ KLİNİK ARAŞTIRMA MANZARASI: BİR ClinicalTrials.gov VERİTABANI DEĞERLENDİRMESİ

Selçuk Şen

Amaç: Klinik araştırmalar bilimsel bilginin ve toplum sağlığının iyileştirilmesi için önemli araçlardır. Bu çalışma ile Türkiye’deki klinik araştırma manzarasının değerlendirilmesi amaçlanmıştır. Yöntem: Türkiye’deki klinik araştırma manzarasının değerlendirilmesi için 20.06.2019 tarihi ve öncesinde ClinicalTrials.gov veritabanına kayıt edilmiş tüm klinik araştırmalar kullanılmıştır. Kayıtlı klinik araştırmalar çalışma türü, çalışma fazı, destekleyici türü, çalışmanın şu anki durumu ve lokasyona göre filtrelenmiştir. Ek olarak, Türkiye’deki klinik araştırma sayısı, nüfus ve çalışma sayısına göre seçilen bazı ülkeler ile kıyaslanmıştır. Bulgular: Türkiye’de toplam kayıtlı klinik araştırma sayısı 3880 idi. Bu araştırmaların çoğunluğu (%74,6) müdahaleli çalışmalardı. Faz çalışmalarının çoğunluğu faz III çalışmalardı ve bu çalışmaların büyük çoğunluğu endüstri tarafından finanse edilmiştir. Tamamlanan ve şu anda aktif olarak katılımcı alan çalışma sayısı sırasıyla 2245 ve 722 idi. Sadece Türkiye’de değil, tüm ülkelerde, durumu bilinmeyen klinik araştırma ve fazı tanımlanmamış faz çalışması sayıları endüstri tarafından desteklenmeyen araştırmalarda daha fazlaydı. Türkiye’de 2009 ve 2018 yılları arasında ilk kez kayıt edilen araştırma sayıları değerlendirildiğinde, gözle görülür bir artış görüldü. Fransa, Almanya ve Birleşik Krallık gibi nüfusu yakın gelişmiş ülkeler ile kıyaslandığında, Türkiye’deki klinik araştırma sayısı 5 veya 6 kat daha azdı. Sonuç: Bu çalışma ile Türkiye’deki klinik araştırma sayısının hala yeterli düzeyde olmadığı gösterildi. Küresel dünyada hak ettiği yeri alması için, Türkiye klinik araştırma alanında iyileştirmeler yapmaya, potansiyelini kullanmaya ve farkındalığı arttırmaya devam etmelidir.


PDF View

References

  • 1. Mhaskar R, Miladinovic B, Guterbock TM, Djulbegovic B. When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open 2016;6:e011150. [CrossRef] google scholar
  • 2. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2018;16:1108-35. [CrossRef] google scholar
  • 3. Ilbars H, Kavakli K, Akan H, Irmak DK. Clinical Trials Journey of Turkey-Long and Thin Road. J Clin Trials 2015;5:211-5. google scholar
  • 4. Ilbars H. Clinical Trials in Turkey. Turkish Journal of Hematology 2013;30(2):111-4. [CrossRef] google scholar
  • 5. T.C. Ministry of Health Turkish Medicine and Medical Devices Agency. Available: www.titck.gov.tr. Accessed: 20 June 2019. google scholar
  • 6. U.S. National Library of Medicine. Available: clinicaltrials. gov. Accessed: 21 June 2019. google scholar
  • 7. The World Bank. Available: data.worldbank.org. Accessed: 21 June 2019. google scholar
  • 8. Califf, RM, Zarin, DA, Kramer, JM, Sherman, RE, Aberle, LH, Tasneem, A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012;307:1838-47. [CrossRef] google scholar
  • 9. Laterre PF, François B. Strengths and limitations of industry vs. academic randomised controlled trials. Clin Microbiol Infect 2015;21:906-9. [CrossRef] google scholar
  • 10. Heinemann L. Are all clinical studies sponsored by industry not valid? J Diabetes Sci Technol 2008;2:1161-3. [CrossRef] google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Şen, S. (2020). THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE. Journal of Istanbul Faculty of Medicine, 83(3), 280-285. https://doi.org/10.26650/IUITFD.2019.0053


AMA

Şen S. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE. Journal of Istanbul Faculty of Medicine. 2020;83(3):280-285. https://doi.org/10.26650/IUITFD.2019.0053


ABNT

Şen, S. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 83, n. 3, p. 280-285, 2020.


Chicago: Author-Date Style

Şen, Selçuk,. 2020. “THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE.” Journal of Istanbul Faculty of Medicine 83, no. 3: 280-285. https://doi.org/10.26650/IUITFD.2019.0053


Chicago: Humanities Style

Şen, Selçuk,. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE.” Journal of Istanbul Faculty of Medicine 83, no. 3 (Nov. 2024): 280-285. https://doi.org/10.26650/IUITFD.2019.0053


Harvard: Australian Style

Şen, S 2020, 'THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE', Journal of Istanbul Faculty of Medicine, vol. 83, no. 3, pp. 280-285, viewed 20 Nov. 2024, https://doi.org/10.26650/IUITFD.2019.0053


Harvard: Author-Date Style

Şen, S. (2020) ‘THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE’, Journal of Istanbul Faculty of Medicine, 83(3), pp. 280-285. https://doi.org/10.26650/IUITFD.2019.0053 (20 Nov. 2024).


MLA

Şen, Selçuk,. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE.” Journal of Istanbul Faculty of Medicine, vol. 83, no. 3, 2020, pp. 280-285. [Database Container], https://doi.org/10.26650/IUITFD.2019.0053


Vancouver

Şen S. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE. Journal of Istanbul Faculty of Medicine [Internet]. 20 Nov. 2024 [cited 20 Nov. 2024];83(3):280-285. Available from: https://doi.org/10.26650/IUITFD.2019.0053 doi: 10.26650/IUITFD.2019.0053


ISNAD

Şen, Selçuk. THE CLINICAL TRIALS LANDSCAPE IN TURKEY: AN EVALUATION OF THE ClinicalTrials.gov DATABASE”. Journal of Istanbul Faculty of Medicine 83/3 (Nov. 2024): 280-285. https://doi.org/10.26650/IUITFD.2019.0053



TIMELINE


Submitted16.07.2019
Accepted24.10.2019
Published Online29.06.2020

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.